[Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis]

Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Mengarelli C
Record ID 32014000261
Authors' objectives: To assess the available evidence on the efficacy, safety and coverage related aspects regarding the use of etanercept, adalimumab, infliximab and golimumab in patients with Juvenile Idiopathic Arthritis.
Authors' recommendations: The evidence found is high quality. JIA treatment with etanercept and adalimumab has demonstrated to improve disease relapse. The use of etanercept is accepted by regulatory agencies, health sponsors and CPG. The use of adalimumab is less homogeneous and depends on local costs and availability. Infliximab has not been approved by the FDA and ANMAT and golimumab is under Phase II research for JIA. They are indicated for patients 4 to 17 years old whose disease remains active with involvement in 5 or more joints after 3-6 months of treatment with methotrexate and another disease-modifying drug. They are not recommended for systemic forms with no joint involvement.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Arthritis, Juvenile
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.